Incyte Corporation (INCY)

86.43
NASDAQ
Prev Close 86.43
Day Low/High 0.00 / 0.00
52 Wk Low/High 55.00 / 133.62
Exchange NASDAQ
Shares Outstanding 187.62B
Market Cap 16.21B
Div & Yield N.A. (N.A)

Latest News

Incyte To Report Second Quarter Financial Results

Incyte To Report Second Quarter Financial Results

Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter 2016 financial results conference call and webcast for 10:00 a.

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

TheStreet highlights 3 stocks pushing the health care sector lower today.

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

FDA Grants Breakthrough Therapy Designation For Incyte's Ruxolitinib (Jakafi®) In Acute Graft-Versus-Host Disease (GVHD)

FDA Grants Breakthrough Therapy Designation For Incyte's Ruxolitinib (Jakafi®) In Acute Graft-Versus-Host Disease (GVHD)

Incyte Corporation (Nasdaq: INCY) today announced that the U.S.

Incyte Announces First Patient Treated In ECHO-301 Phase 3 Study

Incyte Announces First Patient Treated In ECHO-301 Phase 3 Study

Incyte Corporation (Nasdaq: INCY) today announced that the first patient has been treated in the ECHO-301 study—a Phase 3 trial evaluating epacadostat, Incyte's investigational, highly potent and selective oral IDO1...

New Phase 3 Data Show Jakafi® (ruxolitinib) Is Superior To Best Available Therapy In Patients With Polycythemia Vera (PV)

New Phase 3 Data Show Jakafi® (ruxolitinib) Is Superior To Best Available Therapy In Patients With Polycythemia Vera (PV)

Incyte Corporation (Nasdaq: INCY) today announced new 28-week data from the Phase 3 RESPONSE-2 study of Jakafi ® (ruxolitinib).

Five-year Results From Phase 3 Study Of Jakafi® (ruxolitinib) Show Sustained Overall Survival Benefit In Patients With Myelofibrosis (MF)

Five-year Results From Phase 3 Study Of Jakafi® (ruxolitinib) Show Sustained Overall Survival Benefit In Patients With Myelofibrosis (MF)

Incyte Corporation (Nasdaq:INCY) today announces five-year data from the Phase 3 COMFORT-I study evaluating the long-term safety and efficacy of Jakafi ® (ruxolitinib) in patients with intermediate-2 or high-risk...

Incyte And Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance

Incyte And Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance

Incyte Corporation (Nasdaq: INCY) and Moffitt Cancer Center today announced that they have entered into a research support and collaboration agreement, whereby Incyte has agreed to provide funding to conduct three new...

Incyte Announces The Launch Of The Incyte Charitable Giving Foundation

Incyte Announces The Launch Of The Incyte Charitable Giving Foundation

Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company, today announced the launch of the Incyte Charitable Giving Foundation, which will provide charitable donations to publicly-funded 501(c)(3) tax-exempt...

3 Health Care Stocks Pushing Sector Growth

3 Health Care Stocks Pushing Sector Growth

TheStreet highlights 3 stocks pushing the health care sector higher today.

Investors Eager for Gilead to Make Big Moves

Investors Eager for Gilead to Make Big Moves

Jim Cramer likes Gilead but says investors are waiting for the biopharmaceutical company to make a more transformative move.

Gilead (GILD) Shares Spike After Executive Board Appointment

Gilead (GILD) Shares Spike After Executive Board Appointment

Analysts say the drugmaker is a good investment for short-term buyers or those who bet on risk.

Incyte Highlights Jakafi® (ruxolitinib) And Capmatinib Abstracts To Be Presented At The 2016 ASCO And EHA Annual Meetings

Incyte Highlights Jakafi® (ruxolitinib) And Capmatinib Abstracts To Be Presented At The 2016 ASCO And EHA Annual Meetings

Incyte Corporation (Nasdaq: INCY) announces that more than 20 abstracts featuring its clinical development candidates will be presented at the 2016 American Society of Clinical Oncology (ASCO) and European Hematology...

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at...

Incyte Buys European Business Hub From Ariad Pharma

Incyte Buys European Business Hub From Ariad Pharma

Incyte chose to buy a turnkey European commercial operation instead of building one.

Incyte First Quarter Financial Results Conference Call And Webcast

Incyte First Quarter Financial Results Conference Call And Webcast

Incyte Corporation (Nasdaq: INCY) today confirms the details for its first quarter 2016 financial results conference call and webcast for 10:00 a.

Incyte Reports 2016 First-Quarter Financial Results And Updates Shareholders On Key Clinical Programs

Incyte Reports 2016 First-Quarter Financial Results And Updates Shareholders On Key Clinical Programs

Incyte Corporation (Nasdaq: INCY) today reported 2016 first-quarter financial results, including strong revenue growth driven by increased Jakafi ® (ruxolitinib) sales in the U.

The New #44 Most Shorted Nasdaq 100 Component: Incyte

The New #44 Most Shorted Nasdaq 100 Component: Incyte

The most recent short interest data has been released for the 04/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May: Bank of America Merrill Lynch 2016 Health Care Conference on Wednesday,...

Incyte (INCY) Weak On High Volume

Incyte (INCY) Weak On High Volume

Trade-Ideas LLC identified Incyte (INCY) as a weak on high relative volume candidate

Incyte Investor Event At AACR 2016 To Highlight Innovative And Diversified Research And Development Portfolio

Incyte Investor Event At AACR 2016 To Highlight Innovative And Diversified Research And Development Portfolio

Incyte Corporation (Nasdaq: INCY) will highlight the productivity of its drug discovery and development organization and aspects of its development portfolio at an investor event on Sunday, April 17, 2016 at the American...

Incyte To Report First Quarter Financial Results

Incyte To Report First Quarter Financial Results

Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter 2016 financial results conference call and webcast for 10:00 a.

Incyte Acquires Rights From Lilly To Develop And Commercialize Ruxolitinib (Jakafi®) For The Treatment Of Patients With Graft-Versus-Host Disease (GVHD)

Incyte Acquires Rights From Lilly To Develop And Commercialize Ruxolitinib (Jakafi®) For The Treatment Of Patients With Graft-Versus-Host Disease (GVHD)

Incyte Corporation (Nasdaq:INCY) today announced it has acquired the rights to develop and commercialize ruxolitinib (Jakafi ®), its proprietary JAK1/JAK2 inhibitor, for graft-versus-host disease (GVHD) from Eli Lilly...

Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter

Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter

When it comes to the first quarter of 2016, it was the worst of times or it was the best of times, Cramer says

Strong On High Relative Volume: Incyte (INCY)

Strong On High Relative Volume: Incyte (INCY)

Trade-Ideas LLC identified Incyte (INCY) as a strong on high relative volume candidate

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.